Dementia and Alzheimer Disease

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Most of the 52 cognitive resilience proteins were found to be specific for cognitive decline and about 30% may provide resilience for both cognitive and noncognitive AD phenotypes.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 11, 2022.

The founding chair of the department of brain health at the University of Nevada Las Vegas provided background on how a newly funded NIH grant will contribute to translational neuroscience research infrastructure. [WATCH TIME: 3 minutes]

Investigators also found that this association was particularly pronounced among those living in nursing homes, as well as in Asian, Black, and Hispanic populations.

The neurodegeneration program lead at Genentech offered his perspective on the phase 3 SKYLINE trial and the historical data on gantenerumab ahead of this new clinical assessment.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is nutrition in multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 4, 2022.

The trial will use PACC-5 score as its primary end point and expects to enroll 1200 participants who have confirmed amyloid pathology without signs of cognitive impairment.

The treatment is being developed as a first-in-class regenerative therapy for those with AD and dementia, with these safety data offering support to its development.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 25, 2022.

The director of Geriatric Psychiatry at the St Louis University School of Medicine discussed the need to improve awareness of the signs of psychiatric-related symptoms and to eliminate the stigmas associated with them. [WATCH TIME: 3 minutes]

The resubmission includes additional data from the phase 2 Study -019 and the pivotal phase 3 HARMONY study, which showed a significant 2.8-fold reduction in the risk of relapse of psychosis.

The Samuel W. Fordyce professor and director of Geriatric Psychiatry at the St Louis University School of Medicine discussed the critical roles specialists and caregivers during telehealth visits in long-term care settings. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The director of Geriatric Psychiatry at the St Louis University School of Medicine discussed what clinicians should pay attention to when conducting telehealth visits for psychosis-related symptoms in patients with neurodegenerative diseases. [WATCH TIME: 3 minutes]

Imad Najm, MD, provided commentary on the long-term efforts needed to understand the origins of neurological brain diseases and his desire to copy the success of the cardiovascular field.

Neurology News Network for the week ending February 19, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 18, 2022.

The director of Cleveland Clinic’s Epilepsy Center discussed the currently known overlap between neurological diseases and the need to identify causative biomarkers. [WATCH TIME: 4 minutes]

Slightly over one-fourth of the surveyed cohort who were concerned about Alzheimer disease reported “some” or a “fair amount” of knowledge of aducanumab (Aduhelm; Biogen).

With the physician deficit projected to grow larger within a decade, this global challenge has become a major focus of large organizations and medical societies.

Among participants with high sleep efficiency, those who received transcranial direct current stimulation benefitted more from language therapy than those who received sham, whereas those with low sleep efficiency demonstrated no additional benefit.